Middle East And Africa Pemetrexed Market Size & Outlook, 2025-2033


Middle East And Africa Pemetrexed Market Insights

  • As highlighted in Reed Intelligence analysis, the Middle East And Africa Pemetrexed Market, valued at USD 226.28 Million in 2024, is estimated to achieve USD 261.67 Million by 2033.
  • The market is estimated to grow at a CAGR of 1.68% spanning 2026 to 2033.
  • By market size, Malignant Pleural Mesothelioma led the By Application category in 2024.
  • The By Application segment led by Non-Squamous NSCLC is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.

Other Key Findings


  • In 2024, Middle East And Africa accounted for 9.67% of the global Pemetrexed Market size.
  • By 2033, United States is projected to lead the global market in terms of market size.
  • Nigeria is projected to emerge as the fastest-growing market in Middle East and Africa, reaching USD 13.89 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 226.28 Million
Market Size In 2033 USD 261.67 Million
Largest segment Malignant Pleural Mesothelioma
Units Revenue in USD Million
CAGR 1.68% (2025-2033)
Segmnetation Covered
Middle East and Africa
  1. United Arab Emirates
  2. Saudi Arabia
  3. South Africa
  4. Egypt
  5. Nigeria
  6. Turkey
By Application
  1. Malignant Pleural Mesothelioma
  2. Non-Squamous NSCLC
By End-User
  1. Hospitals
  2. Oncology Centers
  3. Online Pharmacies
  4. Offline Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends